Author(s): Marwa Mansour, Rana Makhous

Email(s): ,

DOI: 10.52711/0974-360X.2023.00749   

Address: Marwa Mansour1*, Rana Makhous2
1Master Student, Department of Pharmacology and Toxicology, College of Pharmacy, Tishreen University, Latakia, Syria.
2Professor in the Department of Pharmacology and Toxicology.
*Corresponding Author

Published In:   Volume - 16,      Issue - 10,     Year - 2023

Background: C-reactive protein (CRP) is linked to inflammation and elevated cardiovascular risk in metabolic disorders. Metformin has been shown to lower CRP concentrations. However, it is still unclear whether elevated CRP levels could be modulated by metformin. Objective: This study aims to evaluate the effects of metformin and its combinations on CRP levels in T2DM patients. Patients and Methods: a prospective comparative study was carried out at Tishreen University Hospital and some private diabetic clinics in Lattakia, Syria during the period between April 2020 and March 2022.The study included three groups of patients: group I (31 patients, 32.6%) received metformin at a dose of 1,000mg/d, group II (30 patients, 31.6%) received modified release gliclazide (60mg/d) and group III (34 patients, 35.8%) received metformin with sitagliptin (50/1000mg/d). CRP levels were measured at baseline and after 3 months of treatment. Results: a total of 95 patients, 55males (57.90%) and 40 females (42.1%) with a mean age of 50.72±6.6 years were included in the study. There were no significant differences between the three groups regarding age, sex, and BMI (p > 0.05). There was a significant decrease in FPG after treatment with metformin, gliclazide, and metformin with sitagliptin; 21.92%, 18.75%, and 24.39% respectively, p<0.0001. Metformin, gliclazide, and metformin with sitagliptin significantly reduced HbA1c by 18.7%, 17.36%, and 21.92% respectively. There was a significant change in CRP levels from baseline after receiving metformin (2.06±0.8 vs 3.46±0.9, p<0.001), and metformin with sitagliptin (1.84±0.6 vs 3.30±0.7, p:0<0001). However, the reduction in gliclazide group wasn’t significant (2.97±0.6 vs 3.14±1.1, p=0.09). Reduction in CRP levels wasn't influenced by age, sex or BMI, and was independent of glycemic control (p > 0.05). Conclusion: We demonstrated that metformin and its combination with sitagliptin have a favorable beneficial effect on inflammation marker CRP in patients with T2DM.

Cite this article:
Marwa Mansour, Rana Makhous. The effect of Metformin and its combinations with other hypoglycemic agents on CRP blood levels. Research Journal of Pharmacy and Technology 2023; 16(10):4602-6. doi: 10.52711/0974-360X.2023.00749

Marwa Mansour, Rana Makhous. The effect of Metformin and its combinations with other hypoglycemic agents on CRP blood levels. Research Journal of Pharmacy and Technology 2023; 16(10):4602-6. doi: 10.52711/0974-360X.2023.00749   Available on:

1.    Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison's Principles of Internal Medicine, 19e: Mcgraw-hill New York, NY, USA: 2015.
2.    Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology. 2018;14(2)
3.    Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Research and Clinical Practice. 2014;105(2)
4.    Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. The Journal of Clinical Investigation. 2006;116(7)
5.    Kakar M, Chakarborty P, Behl T, Singh S, Sharma N, Sachdeva M. Insight into the role of Inflammation in progression of diabetes associated neuropathy. Res J Pharm Technol. 2020;13(11)  
6.    Bhattacharya K, Sengupta P, Dutta S, Bhattacharya S. Pathophysiology of obesity: endocrine, inflammatory and neural regulators. Research Journal of Pharmacy and Technology. 2020;13(9)
7.    Pagana K, Pagana T, Pagana T. Mosby's Diagnostic & Laboratory Test Reference. 14th edn St. Louis, Mo: Elsevier. 2019.
8.    Ganapathi A, Roy A, Savitha G. Estimation of C-Reactive Protein in Cardiovascular Disease Patients. Research Journal of Pharmacy and Technology. 2018;11(8)
9.    Khayat MI, Zrieki A. Association of High sensitivity C-reactive protein (Hs-CRP) with poor Glycaemic control and Coronary Heart Disease in Type 2 Diabetes Mellitus. Research Journal of Pharmacy and Technology. 2023;16(1)
10.    Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011;34(6)
11.    Bolen S, Tseng E, Hutfless S, Segal JB, Suarez-Cuervo C, Berger Z, et al. Diabetes medications for adults with type 2 diabetes: an update. 2016.
12.    Suraj B, Tripathi C, Biswas K, Padhy B, Arora T. A comparative evaluation of safety, efficacy and cost effectiveness of three add on treatment regimens in type 2 diabetics; not controlled by metformin alone. Research Journal of Pharmacy and Technology. 2015;8(1)
13.    Babu A, Veerasamy R, Sivadasan S. Metformin-A drug of plant origin. Research Journal of Pharmacy and Technology. 2018;11(6)
14.    Mazumder A, Singh A. A review on metformin: Clinical significance and side effects. Research Journal of Pharmacy and Technology. 2021;14(11)
15.    Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9)
16.    Sreejith K, Velraj M. Association between Metformin and Cognitive impairment-A Review. Research Journal of Pharmacy and Technology. 2020;13(2)
17.    Priyadharshini A, Ahalya S, Alex M, Mathew SE. Overview of Metformin as a Host Targeted Therapy in Tuberculosis. Research Journal of Pharmacy and Technology. 2019;12(7)
18.    Saisho Y. Metformin and inflammation: its potential beyond glucose-lowering effect. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 2015;15(3)
19.    Shaty MH, Al-Ezzi MI, Arif IS, Basil D. Effect of Metformin on inflammatory markers involved in Cardiotoxicity induced by Doxorubicin. Research Journal of Pharmacy and Technology. 2019;12(12)
20.    Kavyasree A, Geetha P, Shanmugasundaram P. A review: Comparison of efficacy of liraglutide versus sitagliptin add-on-to metformin in Type 2 diabetes mellitus patients. Research Journal of Pharmacy and Technology. 2021;14(4)
21.    N. Gamit, N. Kantharia, K. Vaghasiya, A. Vataliya and A. Shah.International Journal of Basic & Clinical Pharmacology. 2015;
22.    Selvi P, Elizabeth AA. Effect of Metformin on C-reactive Protein in Type 2 Diabetes Mellitus Patients. Journal of Pharmaceutical Research International. 2021;33(23B)
23.    Wei Y, Wu Y, Hu L, Meng Z. Effect of sitagliptin phosphate combined with metformin on blood glucose control and microinflammatory status in type 2 diabetes mellitus. Chinese Journal of Postgraduates of Medicine.
24.    Karbalaee-Hasani A, Khadive T, Eskandari M, Shahidi S, Mosavi M, Nejadebrahimi Z, et al. Effect of metformin on circulating levels of inflammatory markers in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Annals of Pharmacotherapy. 2021;55(9)
25.    Abdulkadir AA, Thanoon IA. Comparative effects of glibenclamide and metformin on C-reactive protein and oxidant/antioxidant status in patients with type II diabetes mellitus. Sultan Qaboos University Medical Journal. 2012;12(1)
26.    Li S-N, Wang X, Zeng Q-T, Feng Y-B, Cheng X, Mao X-B, et al. Metformin inhibits nuclear factor κB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits. Heart and Vessels. 2009;
27.    Maheshwari P, Shanmugarajan T. Evaluation of Prescribing Practices of Metformin in Patients with Type-2 Diabetes Mellitus. Research Journal of Pharmacy and Technology. 2019;12(2)
28.    Lima-Martínez MM, Paoli M, Rodney M, Balladares N, Contreras M, D’Marco L, et al. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study. Endocrine. 2016;

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available